Biotechnology
Your CDMO contracts, your CRO relationships, your clinical data, and your China partnerships are governed by a system your organization experiences in fragments. Regulatory sees one gate, legal sees another, commercial sees a market. The system is unified, it is moving on a published schedule, and it will reach your programs whether or not anyone on your team is watching it whole. We watch it whole, and we tell you what to do about it.
What you get
A clear map of your exposure across entry, activity, and exit controls. Early warning on the regulatory cascade before it reaches your filings. Deal terms and partner-structure findings your counterparties did not volunteer. Board-ready answers on the questions BIOSECURE has put on a clock.
Recent work
A briefing prepared for an audience of biotechnology chief executives on China’s biological sovereignty architecture and what it changes for US firms. Exposure mapping against the three-gate control system. An assessment of how US restrictions are accelerating Chinese self-sufficiency, and what that means for firms with manufacturing and data inside the perimeter.
Why clients choose this practice
Our findings come from primary Chinese government sources most advisory teams have never read, which is why our clients hear about the shift first.
The Pacific Divide · Firm Report
The Genome Is the New Chip
The biological sovereignty architecture, briefed to biotechnology chief executives.